MFN2 and metabolic dysfunction-associated steatotic liver disease: Finally, MFN2 has also been associated with progression of liver diseases such as acute-on-chronic liver failure (ACLF) and NAFLD (Wang et al., 2013; Hernández-Alvarez et al., 2019; Xue et al., 2019a,b) and proposed as a possible therapeutic target for hepatic inflammation and fibrosis (Zhu et al., 2020).